

BUPRENORPHINE IN LOUISIANA



LOUISIANA OPIOID SURVEILLANCE PROGRAM

LDH BUREAU OF HEALTH INFORMATICS
AUGUST 2022

PREPARED BY:
TRANETTEA WILLIAMS
MELINDA WILLIAMS
ANNE-SOPHIE LASLEY



WHAT IS BUPRENORPHINE?

Buprenorphine is a medication approved by the Food and Drug Administration (FDA) to treat Opioid Use Disorder (OUD) as a medication-assisted treatment (MAT). As with all medications used in MAT, buprenorphine should be prescribed as part of a comprehensive treatment plan that includes counseling and other behavioral therapies to provide patients with a whole-person approach.

Buprenorphine is the first medication to treat OUD that can be prescribed or dispensed in physician offices, significantly increasing access to treatment.

Buprenorphine offers several benefits to those with OUD and to others for whom treatment in a methadone clinic is not appropriate or is less convenient.

The following buprenorphine products are FDA approved for the treatment of OUD:

- Generic Buprenorphine/naloxone sublingual tablets
- Buprenorphine sublingual tablets (Subutex)
- Buprenorphine/naloxone sublingual films (Suboxone)
- Buprenorphine/naloxone sublingual tablets (Zubsolv)
- Buprenorphine/naloxone buccal film (Bunavail)
- Buprenorphine implants (Probuphine)
- Buprenorphine extended-release injection (Sublocade)






BUPRENORPHINE IN THE PRESCRIPTION MONITORING PROGRAM (PMP)

The Prescription Monitoring Program (PMP) is the statewide electronic database housed under the Louisiana Board of Pharmacy (<http://www.pharmacy.la.gov/>) that tracks the number and type of controlled prescription medicines filled by pharmacists. Prescribers, pharmacists, and other healthcare professionals use this system to ensure that buprenorphine is appropriately prescribed and not misused. This fact sheet provides information on buprenorphine prescriptions in totals, demographics, and changes over time in relation to the number of people in Louisiana.


The PMP started tracking prescriptions of buprenorphine in 2017. Prescribing decreased in 2018; from 2018 through 2021, there has been a slight increase in buprenorphine prescriptions. From 2017 through 2021, 2018 showed the lowest number of total buprenorphine prescriptions per year, while 2021 showed the highest number of prescriptions per year. Between 2017 to 2021, there has been a 7.5% increase in the number of buprenorphine prescriptions dispensed in Louisiana.




BUPRENORPHINE PRESCRIPTIONS BY PARISH AND AGE

Buprenorphine prescriptions in Louisiana were also examined by prescriber parish as well as by age from 2017 through 2021. The total number of prescriptions issued is illustrated in the graphs below.

**Total Buprenorphine Prescriptions by Prescriber Parish
Louisiana, 2018-2021**




**Total Buprenorphine Prescriptions by Age
Louisiana, 2017-2021**



BUPRENORPHINE PRESCRIPTIONS BY PARISH

Top 10 2019	Top 10 2020	Top 10 2021
Jefferson	Jefferson	Jefferson
St. Tammany	St. Tammany	St. Tammany
Caddo	Caddo	Caddo
Tangipahoa	Orleans	Orleans
Livingston	Livingston	Livingston
Orleans	Tangipahoa	Tangipahoa
Calcasieu	Calcasieu	Rapides
Lafayette	East Baton Rouge	Ouachita
East Baton Rouge	Ouachita	Calcasieu
Ouachita	Lafayette	East Baton Rouge

PAYMENT METHODS FOR BUPRENORPHINE PRESCRIPTIONS



The chart above shows the number of persons, by insurance type, receiving Buprenorphine prescriptions from 2017 - 2021 in Louisiana. PMP data revealed a 23% increase in Medicaid payments. By comparison, the number of persons using commercial insurance for Buprenorphine decreased about 17% from 2017-2021.

RESOURCES

<https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/buprenorphine>
PMP (<http://www.pharmacy.la.gov/>)